BIOVF (Swedish Orphan Biovitrum AB) Pre-Tax Income : $419 Mil (TTM As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Swedish Orphan Biovitrum AB's pretax income for the three months ended in Dec. 2024 was $131 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $419 Mil. Swedish Orphan Biovitrum AB's pretax margin was 19.32%.

During the past 13 years, Swedish Orphan Biovitrum AB's highest Pretax Margin was 33.72%. The lowest was 2.61%. And the median was 20.68%.

Swedish Orphan Biovitrum AB Pre-Tax Income Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Pre-Tax Income Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

Get a 7-Day Free Trial

504.24

362.50

320.00

287.98

401.18

Swedish Orphan Biovitrum AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial															120.59	94.32	26.22	167.37	130.82

Competitive Comparison of Swedish Orphan Biovitrum AB's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Pre-Tax Income falls into.

Save Embed

Swedish Orphan Biovitrum AB Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Swedish Orphan Biovitrum AB's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	512.062	+	0	+	-110.97	+	0	+	0.091000000000008
	=	401

Swedish Orphan Biovitrum AB's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	151.206	+	0	+	-20.482	+	0	+	0.091000000000008
	=	131

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $419 Mil.

Swedish Orphan Biovitrum AB (OTCPK:BIOVF) Pre-Tax Income Explanation

Swedish Orphan Biovitrum AB's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	130.815	/	676.923
	=	19.32%

During the past 13 years, Swedish Orphan Biovitrum AB's highest Pretax Margin was 33.72%. The lowest was 2.61%. And the median was 20.68%.

Swedish Orphan Biovitrum AB Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:BIOVF) » Definitions » Pre-Tax Income

Traded in Other Exchanges

SWOBY:USA SOBI:Sweden SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).